The Summary of Product Characteristics (SPC) for Dexdomitor 0.5 mg/ml solution for injection for dogs and cats has been updated. This change now includes intravenous administration as a constant rate infusion (CRI) for both species as part of a multimodal protocol during inhalation anaesthesia.
The updated SPC highlights the need for adequate monitoring of respiratory and cardiovascular functions, oxygen supplementation, and access to mechanical ventilation during CRI. Adverse events reported for dogs include very common occurrences of arrhythmia, bradycardia, heart block, and vomiting, with hypotension being common. For cats, very common adverse events include bradycardia, heart block, high or low blood pressure, decreased pulse oxygenation, hypersalivation, vomiting, muscle twitching, agitation, prolonged recovery, and vocalisation.
The updated SPC will be available on the Product Information Database (PID) once approved by the VMD, though it may take up to 12 months for these changes to appear on marketed packaging. The reporting of adverse events is encouraged to either the Marketing Authorisation Holder or the VMD to support ongoing monitoring activities.